Detail akcie ENDRA Life Rg online

Business Summary: ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, ENDRA Life Sciences Inc revenues was not reported. Net loss decreased 48% to $3.9M. Lower net loss reflects Warrant expense decrease from $7.3M (expense) to $0K, Research and development decrease of 47% to $1.3M (expense), Selling/General/Admin. Expense decrease of 25% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$602.10 to -$5.66.